Polymorphisms of interferon-inducible genes OAS associated with interferon-α treatment response in chronic HBV infection

Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population

“…Previous studies reported combined therapy (IFN plus NUCs), which would affect the accuracy of their findings (de Niet et al, 2012;Sonneveld et al, 2012). Second, previous studies have demonstrated the relationship between PEG-IFN therapeutic efficacy and HBV viral load, host age/sex and ALT level, except for HBV genotype (King et al, 2002;Ren et al, 2011). We reported here that the adjusted data for HBV genotype in a multivariate analysis, as ethnicity was intensively linked to both HBV genotype and host IPS1 genotype distribution.…”

Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B

“…Regarding host genetic factors, it was reported that the HLA-DRB1*010101 allele and TNF-a promoter at position À238 was associated with the response to lamivudine treatment [20,21]. The 2',5-oligoadenylate synthetase, eIF-2a, and MxA gene promoter at nt À88, including IL-28B, may play an important role in the response to IFN with CHB [16,[22][23][24]. On the whole, analyses of the relationship between polymorphisms and responses to lamivudine are rare.…”

Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus

“…The connection between the OAS gene polymorphisms and the efficacy of interferon therapy has not been extensively studied in patients with CHB. A small number of available studies have been carried out only in Han Chinese treatment-naïve CHB patients, who are representative of the Asian population[24,25]. The study of Wu et al[24] demonstrated an association between interferon treatment and the haplotype G-T-G-A within the rs3177979G, rs1293747T, rs4767043G, and rs10849829A alleles, which occur in the OAS1, OAS2, OAS3, and OASL genes, respectively, instead of with OASL rs10849829.…”

“…Additionally, the authors showed that the allele frequencies and genotype distributions of all the examined OAS SNPs were not correlated with treatment outcomes in patients who underwent IFN therapy. In another study conducted by Ren et al[25], the influence of 4 SNPs - rs2285934 OAS1, rs2072138 OAS2, rs2072136 OAS3 and rs10849829 OASL - on the outcome of a 48-week IFN treatment of Han Chinese treatment-naïve CHB patients (265 HBeAg-positive, 55 HBeAg-negative, and 43 inactive HBsAg carriers) was evaluated. In this study, treatment response was defined as HBsAg seroconversion or HBeAg seroconversion for the patients who were HBeAg-positive, without HBsAg seroconversion.…”

“…Unlike many studies confirming that SNPs in the interleukin 28B ( IL28B ) gene play a primary role in IFN-based treatment outcomes in patients with chronic hepatitis C, the association between IL28B SNPs and the result of IFN monotherapy in CHB has been a subject of very few studies[21-23]. Additionally, there is limited information about the role of SNPs in 2’,5’-oligoadenylate synthetase (OAS) family genes in the IFN response in hepatitis B patients[24,25]. Currently, there are no available results concerning the impact of IL28B or OAS SNPs on the results of IFN therapy in a group of paediatric patients with CHB.…”